143 related articles for article (PubMed ID: 31092408)
1. Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.
Murai J; Pommier Y
Cancer Res; 2019 May; 79(10):2460-2461. PubMed ID: 31092408
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
Wang F; Zhu S; Fisher LA; Wang L; Eurek NJ; Wahl JK; Lan L; Peng A
Cancer Res; 2019 May; 79(10):2526-2535. PubMed ID: 30733193
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
4. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
5. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
6. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
[TBL] [Abstract][Full Text] [Related]
7. PARP1-modulated chromatin remodeling is a new target for cancer treatment.
Sinha S; Molla S; Kundu CN
Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanisms of regulaion of transcription by PARP1].
Maliuchenko NV; Kulaeva OI; Kotova E; Chupyrkina AA; Nikitin DV; Kirpichnikov MP; Studitskiĭ VM
Mol Biol (Mosk); 2015; 49(1):99-113. PubMed ID: 25916114
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
11. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
12. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
13. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
14. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
Feng FY; de Bono JS; Rubin MA; Knudsen KE
Mol Cell; 2015 Jun; 58(6):925-34. PubMed ID: 26091341
[TBL] [Abstract][Full Text] [Related]
15. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
[TBL] [Abstract][Full Text] [Related]
16. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region.
Dallavalle S; Princiotto S; Mattio LM; Artali R; Musso L; Aviñó A; Eritja R; Pisano C; Gargallo R; Mazzini S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445442
[TBL] [Abstract][Full Text] [Related]
18. Nuclear PARP1-Targeted Photosensitizer as a Dual-Mode DNA-Damaging Agent and Immune Activator for Tumor Ablation.
Li P; Du Y; Qiu J; Li D; Li G; Shan G
Adv Healthc Mater; 2023 Dec; 12(31):e2301517. PubMed ID: 37689990
[TBL] [Abstract][Full Text] [Related]
19. The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis.
Fujimoto M; Takii R; Takaki E; Katiyar A; Nakato R; Shirahige K; Nakai A
Nat Commun; 2017 Nov; 8(1):1638. PubMed ID: 29158484
[TBL] [Abstract][Full Text] [Related]
20. Single-molecule measurements reveal that PARP1 condenses DNA by loop stabilization.
Bell NAW; Haynes PJ; Brunner K; de Oliveira TM; Flocco MM; Hoogenboom BW; Molloy JE
Sci Adv; 2021 Aug; 7(33):. PubMed ID: 34380612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
